Home  |  Archive  |  Online Submission  |  News & Events  |  Subscribe  |  APFA  |  Society  |  Links  |  Contact Us  |  中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

Links

Meetings
Journals
Societies & Institutes
Hospitals
Databases & Libraries
Companies
Websites
Other links

 
Abstract

Volume 16, Issue 4 (July 2014) 16, 555–560; 10.4103/1008-682X.127824

New developments in the treatment of castration resistant prostate cancer

Roxanne Wadia, Daniel P Petrylak

Department of Medicine, Smilow Cancer Center, Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, Connecticut, USA

Correspondence: Dr. DP Petrylak (daniel.petrylak@yale.edu)

Received: 16 December 2013; Accepted: 12 February 2014 Open Access Prostate

Abstract

In the past 5 years, the treatment and understanding of metastatic castrate resistant prostate cancer (CRPC) have improved dramatically. Our understanding of the mechanisms of castration resistance has allowed for the development of new drugs to target prostate cancer, and our understanding of genetic mutations may give us new tools with which to more accurately diagnose and be able to predict the course of this heterogeneous disease. This article summarizes the recent advances in the understanding of the development of CRPC, as well as the new drugs and targets, which have evolved from this basic research.

Keywords: castration resistant prostate cancer; abiraterone; enzalutamide; chemotherapy; docetaxel; cabazitaxel; PSMA antibody

Full Text | PDF | 中文摘要 |

 
Browse:  1028
 
Copyright 1999-2017  Shanghai Materia Medica, Shanghai Jiao Tong University.  All rights reserved